drugset / Trial / NCT02490865

Systemic Bioactivity of Inhaled Nebulized RNS60

NCT02490865

Phase 1 Completed 56 enrolled Revalesio Corporation
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The study aims to determine the effects of nebulized RNS60 on selected biomarkers in the circulation.

Timeline

Start
2015-07
Primary completion
2015-08
Completion
2015-08

Drugs

EvaluationDrugModalityDoseRoute
Subject RNS60 Other / unclassified 4 ml Inhaled

Indications

No indication recorded.